Esketamine for Treatment-Resistant Depression
A practical guide to esketamine/Spravato, who it may fit, why monitoring is required, and why it belongs under psychiatric supervision.
Psychiatrist
Esketamine is a prescription nasal spray used in specific depression treatment settings. It is not a casual take-home wellness product. Because of risks including sedation, dissociation, and respiratory depression, FDA labeling and the REMS program require treatment in a certified health care setting with monitoring after each session.
Esketamine is generally discussed for treatment-resistant depression or other FDA-labeled depression use cases, not ordinary stress.
SPRAVATO is administered under supervision in a certified health care setting.
Patients are monitored for at least two hours after each treatment session under the REMS program.
Psychiatric oversight matters because candidacy, diagnosis, medications, blood pressure, safety, and follow-up all affect whether this is appropriate.
Why esketamine is not the same as unsupervised ketamine
Esketamine nasal spray is FDA-approved for specific uses and is subject to a REMS safety program. That is different from obtaining compounded or unsupervised ketamine products outside a certified treatment process, even though patients often hear these terms mixed together online.
What supervision protects
Supervision protects against avoidable risk. A clinician has to review the diagnosis, prior treatment response, other medications, blood pressure, substance-use risk, pregnancy considerations when relevant, dissociation risk, sedation risk, transportation after treatment, and what monitoring is required before the patient leaves.
How MWI should frame the next step
The safest next step is not a promise of rapid relief. It is a psychiatric evaluation or referral conversation for men with depression that has not responded adequately to standard care. Public education can explain the treatment, but prescribing and monitoring must happen in the proper clinical setting.